Incyte Clinical Trials Results
April 20, 2023 – Incyte published a press release on European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents.
May 17, 2021 – Incyte published a press release on the success of their Phase 3 Clinical Trial for ruxolitinib.
Incyte is a past and present sponsor of GVF. This is an unpaid post.
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.